Thursday, July 11, 2013
High drug attrition rates from poor safety have spawned
numerous efforts to use in silico methods to improve molecule design,
but none of the algorithms created so far has emerged as a true game changer.
Now, AstraZeneca plc and Roche have concluded that
better prediction requires more data, and they are pooling their information
via an intermediary cheminformatics company, MedChemica Ltd., to produce a new
set of design rules.
Fishburn, C.S. SciBX 6(26); doi:10.1038/scibx.2013.647
Published online July 11, 2013
AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN;
NYSE:AZN), London, U.K.
Genentech Inc., South San Francisco, Calif.
MedChemica Ltd., Newcastle-under-Lyme, U.K.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland